<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03381209</url>
  </required_header>
  <id_info>
    <org_study_id>FMASU R 39/2017</org_study_id>
    <nct_id>NCT03381209</nct_id>
  </id_info>
  <brief_title>The Effect of Sugammadex Given Based on Ideal, Actual or Adjusted Body Weight on Reversal of Rocuronium.</brief_title>
  <official_title>The Effect of Sugammadex Given Based on Ideal, Actual or Adjusted Body Weights on Reversal of Neuromuscular Blockade in Morbidly Obese Patients Undergoing Laparoscopic Bariatric Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ain Shams University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ain Shams University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is compare the reversal of rocuronium induced neuromuscular blockade in
      morbidly obese patients using three doses of sugammadex; based on ideal body weight, adjusted
      body weight, and actual body weight.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of this study is compare the reversal of rocuronium induced neuromuscular blockade in
      morbidly obese patients using three doses of sugammadex; based on ideal body weight, adjusted
      body weight, and actual body weight. Reversal Time: time from administration of Sugammadex to
      train of four (TOF) ratio ≥ 0.9 will be used as primary outcome.

      Time need for extubation (time from administration of sugammadex to extubation), and duration
      of stay in post anesthesia care unit (PACU), will be used as secondary outcome.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 10, 2017</start_date>
  <completion_date type="Actual">November 10, 2017</completion_date>
  <primary_completion_date type="Actual">November 10, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reversal Time</measure>
    <time_frame>5 minutes after sugammadex administration</time_frame>
    <description>Reversal Time: time from administration of Sugammadex to train of four (TOF) ratio ≥ 0.9 will be used as primary outcome.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>duration of stay in PACU</measure>
    <time_frame>60 minutes after admission to the PACU</time_frame>
    <description>period of stay in the PACU</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time need for Extubation</measure>
    <time_frame>10 minutes after sugammadex administration</time_frame>
    <description>time from administration of sugammadex to extubation</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Muscle Relaxation</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sugammadex given in a dose of 2mg/kg based on ideal body weight</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sugammadex given in a dose of 2mg/kg based on adjusted body weight</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sugammadex given in a dose of 2mg/kg based on actual body weight</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sugammadex</intervention_name>
    <description>sugammadex given based on 3 measurements of body weights</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_label>Group C</arm_group_label>
    <other_name>bridion</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients older than 18 years and under 45 years,

          -  body mass index ≥ 40 kg/m2, with indication of bariatric surgery

        Exclusion Criteria:

          -  Patients with comorbid including: neuromuscular disease, renal impairment, and
             patients with difficult airway were excluded from this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Walid Nofal, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Anesthesiology department, Faculty of Medicine, Ain Shams University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Faculty of Medicine, Ain Shams University</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 17, 2017</study_first_submitted>
  <study_first_submitted_qc>December 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 21, 2017</study_first_posted>
  <last_update_submitted>December 20, 2017</last_update_submitted>
  <last_update_submitted_qc>December 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ain Shams University</investigator_affiliation>
    <investigator_full_name>Walid Nofal</investigator_full_name>
    <investigator_title>Lecturer of Anesthesiology</investigator_title>
  </responsible_party>
  <keyword>Sugammadex</keyword>
  <keyword>morbidly obese patients</keyword>
  <keyword>bariatric surgery</keyword>
  <keyword>neuromuscular blockade</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Body Weight</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

